Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET

Company Participants

Christine Cassiano - Chief Communications Officer

David Chang - President & Chief Executive Officer

Zachary Roberts - Executive Vice President-Research and Development & Chief Medical Officer

Eric Schmidt - Chief Financial Officer

Conference Call Participants

Tyler Van Baron - TD Cowen

Michael Yee - Jefferies

Brian Cheng - JPMorgan

Kelsey Goodwin - Guggenheim

John Newman - Canaccord

Jack Allen - Baird

Kalpit Patel - B. Riley

Sami Corwin - William Blair

Luca Issi - RBC Capital

Tony Butler - EF Hutton

Akash Singh - Oppenheimer

Reni Benjamin - JMP Securities

Jason Gerberry - Bank of America Securities

William Pickering - Bernstein

Carolina Ibanez Ventoso - Stifel

Operator

Hello. Thank you for standing by, and welcome to Allogene Therapeutics Second Quarter 2023 Conference Call. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be aware that today's conference is being recorded.

I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.

Christine Cassiano

Thank you, operator, and welcome to our call. Today, after market closed, Allogene issued a press release that provides a business update and financial results for the second quarter of 2023. This press release and today's webcast are both available on our website. Following our prepared remarks, we will host a Q&A session. We ask you to limit your questions to one per person as we will keep this call to an hour and do our best to get to as many questions as possible.

Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Dr. Eric Schmidt, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities and 2023 financial guidance, among other things. These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements and Allogene disclaims any obligation to update these statements.